HRP20100545T1 - Adicijske soli inhibitora angiotenzin-preobražajnog enzima s ne-donorskim kiselinama, postupak njihove priprave i farmaceutske smjese koje ih sadrže - Google Patents

Adicijske soli inhibitora angiotenzin-preobražajnog enzima s ne-donorskim kiselinama, postupak njihove priprave i farmaceutske smjese koje ih sadrže Download PDF

Info

Publication number: HRP20100545T1
Authority: HR; Croatia
Prior art keywords: amino; image; propionyl; group; oxido
Prior art date: 2007-09-21

Application number

HR20100545T

Other languages

English (en)

Croatian (hr)

Inventor

De Nanteuil Guillaume

Portevin Bernard

Gloanec Philippe

Parmentier Jean-Gilles

Benoist Alain

Verbeuren Tony

Rupin Alain

Courchay Christine

Simonet Serge

Original Assignee

Les Laboratoires Servier

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-21

Filing date

2010-10-05

Publication date

2010-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39539691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100545(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-10-05 Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier

2010-11-30 Publication of HRP20100545T1 publication Critical patent/HRP20100545T1/hr

Links

239000002253 acid Substances 0.000 title claims 2
238000000034 method Methods 0.000 title claims 2
150000003839 salts Chemical class 0.000 title claims 2
102000004190 Enzymes Human genes 0.000 title 1
108090000790 Enzymes Proteins 0.000 title 1
150000007513 acids Chemical class 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract 15
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract 6
229910006069 SO3H Inorganic materials 0.000 claims abstract 6
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 6
125000004432 carbon atom Chemical group C* 0.000 claims abstract 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 6
229910052757 nitrogen Inorganic materials 0.000 claims abstract 6
125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 6
229910052760 oxygen Inorganic materials 0.000 claims abstract 6
239000001301 oxygen Substances 0.000 claims abstract 6
229920006395 saturated elastomer Polymers 0.000 claims abstract 6
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims abstract 6
229910052717 sulfur Inorganic materials 0.000 claims abstract 6
239000011593 sulfur Substances 0.000 claims abstract 6
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical group C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims abstract 5
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 3
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims abstract 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 3
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 3
239000002840 nitric oxide donor Substances 0.000 claims abstract 2
229960002582 perindopril Drugs 0.000 claims abstract 2
ODAIHABQVKJNIY-PEDHHIEDSA-N perindoprilat Chemical group C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(O)=O)[C@H]21 ODAIHABQVKJNIY-PEDHHIEDSA-N 0.000 claims abstract 2
229960005226 perindoprilat Drugs 0.000 claims abstract 2
125000002947 alkylene group Chemical group 0.000 claims 6
239000000825 pharmaceutical preparation Substances 0.000 claims 4
229940126062 Compound A Drugs 0.000 claims 2
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
230000015572 biosynthetic process Effects 0.000 claims 2
229910052799 carbon Inorganic materials 0.000 claims 2
125000005843 halogen group Chemical group 0.000 claims 2
229910052739 hydrogen Inorganic materials 0.000 claims 2
239000001257 hydrogen Substances 0.000 claims 2
125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
230000007170 pathology Effects 0.000 claims 2
125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims 2
230000002792 vascular Effects 0.000 claims 2
MUJNOSXJRQJEQW-JTQLQIEISA-N (2s)-2-[3-[[4-(4-chlorophenyl)sulfonyl-5-oxido-1,2,5-oxadiazol-5-ium-3-yl]oxy]propanoylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CCOC1=NO[N+]([O-])=C1S(=O)(=O)C1=CC=C(Cl)C=C1 MUJNOSXJRQJEQW-JTQLQIEISA-N 0.000 claims 1
GBMJEWWQZQAQRM-KFJBMODSSA-N (2s)-2-[3-[[4-(4-methylphenyl)sulfonyl-5-oxido-1,2,5-oxadiazol-5-ium-3-yl]oxy]butanoylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CC(C)OC1=NO[N+]([O-])=C1S(=O)(=O)C1=CC=C(C)C=C1 GBMJEWWQZQAQRM-KFJBMODSSA-N 0.000 claims 1
VAFRJUNTOCQQLZ-NSHDSACASA-N (2s)-2-[3-[[4-(4-methylphenyl)sulfonyl-5-oxido-1,2,5-oxadiazol-5-ium-3-yl]oxy]propanoylamino]butanedioic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1=[N+]([O-])ON=C1OCCC(=O)N[C@@H](CC(O)=O)C(O)=O VAFRJUNTOCQQLZ-NSHDSACASA-N 0.000 claims 1
LAUOKWHMZRAXPV-NSHDSACASA-N (2s)-2-[4-[[4-(benzenesulfonyl)-5-oxido-1,2,5-oxadiazol-5-ium-3-yl]oxy]butanoylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CCCOC1=NO[N+]([O-])=C1S(=O)(=O)C1=CC=CC=C1 LAUOKWHMZRAXPV-NSHDSACASA-N 0.000 claims 1
QNFJPQYJMAPHFO-MHXJNQAMSA-N (2s,3as,7as)-1-[(2s)-2-[[(2s)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid;2-[[4-(benzenesulfonyl)-5-oxido-1,2,5-oxadiazol-5-ium-3-yl]oxy]ethylphosphonic acid Chemical compound OP(O)(=O)CCOC1=NO[N+]([O-])=C1S(=O)(=O)C1=CC=CC=C1.C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 QNFJPQYJMAPHFO-MHXJNQAMSA-N 0.000 claims 1
125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
HTHNPLZEHYQITL-UHFFFAOYSA-N 2-[3-[[4-(benzenesulfonyl)-5-oxido-1,2,5-oxadiazol-5-ium-3-yl]oxy]propanoylamino]ethanesulfonic acid Chemical compound OS(=O)(=O)CCNC(=O)CCOC1=NO[N+]([O-])=C1S(=O)(=O)C1=CC=CC=C1 HTHNPLZEHYQITL-UHFFFAOYSA-N 0.000 claims 1
206010002383 Angina Pectoris Diseases 0.000 claims 1
201000001320 Atherosclerosis Diseases 0.000 claims 1
208000005189 Embolism Diseases 0.000 claims 1
206010048554 Endothelial dysfunction Diseases 0.000 claims 1
206010019280 Heart failures Diseases 0.000 claims 1
206010061218 Inflammation Diseases 0.000 claims 1
206010048620 Intracardiac thrombus Diseases 0.000 claims 1
208000018262 Peripheral vascular disease Diseases 0.000 claims 1
208000007718 Stable Angina Diseases 0.000 claims 1
208000006011 Stroke Diseases 0.000 claims 1
206010042957 Systolic hypertension Diseases 0.000 claims 1
208000007814 Unstable Angina Diseases 0.000 claims 1
208000032594 Vascular Remodeling Diseases 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
208000037849 arterial hypertension Diseases 0.000 claims 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
238000013130 cardiovascular surgery Methods 0.000 claims 1
239000000969 carrier Substances 0.000 claims 1
206010012601 diabetes mellitus Diseases 0.000 claims 1
230000002526 effect on cardiovascular system Effects 0.000 claims 1
230000008694 endothelial dysfunction Effects 0.000 claims 1
230000008798 inflammatory stress Effects 0.000 claims 1
208000010125 myocardial infarction Diseases 0.000 claims 1
231100000252 nontoxic Toxicity 0.000 claims 1
230000003000 nontoxic effect Effects 0.000 claims 1
230000036542 oxidative stress Effects 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
208000037803 restenosis Diseases 0.000 claims 1
238000003786 synthesis reaction Methods 0.000 claims 1
230000002378 acidificating effect Effects 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Toxicology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Obesity (AREA)
Biochemistry (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

HR20100545T 2007-09-21 2010-10-05 Adicijske soli inhibitora angiotenzin-preobražajnog enzima s ne-donorskim kiselinama, postupak njihove priprave i farmaceutske smjese koje ih sadrže HRP20100545T1 (hr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0706629A FR2921365B1 (fr)	2007-09-21	2007-09-21	Nouveaux sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine a des acides donneurs de no, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number	Publication Date
HRP20100545T1 true HRP20100545T1 (hr)	2010-11-30

Family

ID=39539691

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20100545T HRP20100545T1 (hr)	2007-09-21	2010-10-05	Adicijske soli inhibitora angiotenzin-preobražajnog enzima s ne-donorskim kiselinama, postupak njihove priprave i farmaceutske smjese koje ih sadrže

Country Status (43)

Country	Link
US (1)	US7981920B2 (pl)
EP (2)	EP2236495A1 (pl)
JP (1)	JP4903187B2 (pl)
KR (1)	KR101070056B1 (pl)
CN (1)	CN101391973A (pl)
AP (1)	AP2010005204A0 (pl)
AR (1)	AR068488A1 (pl)
AT (1)	ATE476416T1 (pl)
AU (1)	AU2008217013B8 (pl)
BR (1)	BRPI0804073A2 (pl)
CA (1)	CA2639700C (pl)
CL (1)	CL2008002725A1 (pl)
CR (1)	CR11320A (pl)
CY (1)	CY1110782T1 (pl)
DE (1)	DE602008002027D1 (pl)
DK (1)	DK2039682T3 (pl)
EA (1)	EA015092B1 (pl)
EC (1)	ECSP10010040A (pl)
ES (1)	ES2349493T3 (pl)
FR (1)	FR2921365B1 (pl)
GE (1)	GEP20125479B (pl)
HN (1)	HN2010000533A (pl)
HR (1)	HRP20100545T1 (pl)
JO (1)	JO2664B1 (pl)
MA (1)	MA30320B1 (pl)
MX (1)	MX2008011954A (pl)
MY (1)	MY144927A (pl)
NI (1)	NI201000038A (pl)
NZ (1)	NZ572988A (pl)
PA (1)	PA8796701A1 (pl)
PE (1)	PE20091190A1 (pl)
PL (1)	PL2039682T3 (pl)
PT (1)	PT2039682E (pl)
RS (1)	RS51433B (pl)
SA (1)	SA08290599B1 (pl)
SG (1)	SG151200A1 (pl)
SI (1)	SI2039682T1 (pl)
SV (1)	SV2010003511A (pl)
TN (1)	TN2010000111A1 (pl)
TW (1)	TWI370118B (pl)
UY (1)	UY31339A1 (pl)
WO (1)	WO2009074733A2 (pl)
ZA (1)	ZA200808062B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2961105B1 (fr) *	2010-06-15	2013-02-08	Servier Lab	Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
US10314816B2 (en)	2012-06-08	2019-06-11	Wisconsin Alumni Research Foundation	Antimicrobial compounds, compositions and methods of use thereof
CN103848795B (zh) *	2014-03-07	2016-08-17	山东大学	一种1,2,5-噁二唑-2-氧化物组蛋白去乙酰化酶抑制剂及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4218582A1 (de) *	1992-06-05	1993-12-09	Cassella Ag	Pyridyl-1,2,5-oxadiazol-carbonamid-2-oxide
IT1295694B1 (it) *	1996-11-14	1999-05-27	Nicox Sa	Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
EP1235563A2 (en) *	1998-08-26	2002-09-04	Queen's University At Kingston	Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
DE10033580A1 (de)	2000-04-10	2001-10-11	Bayer Ag	Verfahren zur Herstellung von Ditaurin und seinen Salzen
AUPS236902A0 (en) *	2002-05-16	2002-06-13	Northern Sydney Area Health Service	Composition and method for treating hypertension
WO2004050084A2 (en) *	2002-11-29	2004-06-17	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Ace-inhibitors having antioxidant and nitricoxid-donor activity
JP2007502831A (ja) *	2003-08-20	2007-02-15	ニトロメッドインコーポレーティッド	ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
AU2006206249A1 (en) *	2005-01-21	2006-07-27	Nicox S.A.	Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
AU2006227439A1 (en) *	2005-03-18	2006-09-28	Nicox S.A.	Organic nitric oxide enhancing salts of angiotensin converting enzyme inhibitors, compositions and methods of use
RU2271202C1 (ru) *	2005-05-04	2006-03-10	Михаил Владимирович Покровский	Способ коррекции эндотелиальной дисфункции
WO2007016136A2 (en) *	2005-07-28	2007-02-08	Nitromed, Inc.	Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
WO2007059311A2 (en) *	2005-11-16	2007-05-24	Nitromed, Inc.	Furoxan compounds, compositions and methods of use
WO2007060112A1 (en) *	2005-11-23	2007-05-31	Nicox S.A.	Salicylic acid derivatives

2007
- 2007-09-21 FR FR0706629A patent/FR2921365B1/fr not_active Expired - Fee Related
2008
- 2008-09-11 SG SG200806674-8A patent/SG151200A1/en unknown
- 2008-09-12 PE PE2008001592A patent/PE20091190A1/es not_active Application Discontinuation
- 2008-09-12 CL CL2008002725A patent/CL2008002725A1/es unknown
- 2008-09-12 UY UY31339A patent/UY31339A1/es unknown
- 2008-09-15 AU AU2008217013A patent/AU2008217013B8/en not_active Ceased
- 2008-09-16 GE GEAP200810907A patent/GEP20125479B/en unknown
- 2008-09-16 MA MA31244A patent/MA30320B1/fr unknown
- 2008-09-16 MY MYPI20083604A patent/MY144927A/en unknown
- 2008-09-17 US US12/283,928 patent/US7981920B2/en not_active Expired - Fee Related
- 2008-09-18 CN CNA2008102131384A patent/CN101391973A/zh active Pending
- 2008-09-18 JO JO2008417A patent/JO2664B1/en active
- 2008-09-19 ES ES08290885T patent/ES2349493T3/es active Active
- 2008-09-19 EP EP10075301A patent/EP2236495A1/fr not_active Withdrawn
- 2008-09-19 PT PT08290885T patent/PT2039682E/pt unknown
- 2008-09-19 AR ARP080104074A patent/AR068488A1/es unknown
- 2008-09-19 AP AP2010005204A patent/AP2010005204A0/xx unknown
- 2008-09-19 JP JP2008240538A patent/JP4903187B2/ja not_active Expired - Fee Related
- 2008-09-19 PL PL08290885T patent/PL2039682T3/pl unknown
- 2008-09-19 MX MX2008011954A patent/MX2008011954A/es active IP Right Grant
- 2008-09-19 RS RSP-2010/0403A patent/RS51433B/sr unknown
- 2008-09-19 PA PA20088796701A patent/PA8796701A1/es unknown
- 2008-09-19 AT AT08290885T patent/ATE476416T1/de active
- 2008-09-19 ZA ZA200808062A patent/ZA200808062B/xx unknown
- 2008-09-19 KR KR1020080092197A patent/KR101070056B1/ko not_active Expired - Fee Related
- 2008-09-19 SI SI200830064T patent/SI2039682T1/sl unknown
- 2008-09-19 TW TW097136239A patent/TWI370118B/zh not_active IP Right Cessation
- 2008-09-19 DK DK08290885.6T patent/DK2039682T3/da active
- 2008-09-19 EP EP08290885A patent/EP2039682B1/fr active Active
- 2008-09-19 EA EA200801863A patent/EA015092B1/ru not_active IP Right Cessation
- 2008-09-19 DE DE602008002027T patent/DE602008002027D1/de active Active
- 2008-09-19 WO PCT/FR2008/001311 patent/WO2009074733A2/fr not_active Ceased
- 2008-09-21 SA SA8290599A patent/SA08290599B1/ar unknown
- 2008-09-22 CA CA2639700A patent/CA2639700C/fr not_active Expired - Fee Related
- 2008-09-22 BR BRPI0804073-7A patent/BRPI0804073A2/pt not_active IP Right Cessation
- 2008-11-20 NZ NZ572988A patent/NZ572988A/en not_active IP Right Cessation
2010
- 2010-03-15 TN TNP2010000111A patent/TN2010000111A1/fr unknown
- 2010-03-17 EC EC2010010040A patent/ECSP10010040A/es unknown
- 2010-03-17 CR CR11320A patent/CR11320A/es not_active Application Discontinuation
- 2010-03-18 SV SV2010003511A patent/SV2010003511A/es not_active Application Discontinuation
- 2010-03-19 HN HN2010000533A patent/HN2010000533A/es unknown
- 2010-03-19 NI NI201000038A patent/NI201000038A/es unknown
- 2010-09-15 CY CY20101100834T patent/CY1110782T1/el unknown
- 2010-10-05 HR HR20100545T patent/HRP20100545T1/hr unknown

Also Published As

Publication number	Publication date
CA2639700C (fr)	2012-08-28
FR2921365B1 (fr)	2012-10-12
SI2039682T1 (sl)	2010-10-29
JP2009137935A (ja)	2009-06-25
AU2008217013A8 (en)	2012-10-04
AR068488A1 (es)	2009-11-18
EP2039682A1 (fr)	2009-03-25
SG151200A1 (en)	2009-04-30
UY31339A1 (es)	2008-10-31
SA08290599B1 (ar)	2011-05-04
EP2039682B1 (fr)	2010-08-04
CL2008002725A1 (es)	2009-06-12
TW200920352A (en)	2009-05-16
MX2008011954A (es)	2009-03-20
CA2639700A1 (fr)	2009-03-21
JO2664B1 (en)	2012-06-17
SV2010003511A (es)	2010-07-29
EA200801863A1 (ru)	2009-04-28
WO2009074733A3 (fr)	2009-08-20
US7981920B2 (en)	2011-07-19
MY144927A (en)	2011-11-30
ATE476416T1 (de)	2010-08-15
BRPI0804073A2 (pt)	2009-06-16
NZ572988A (en)	2010-07-30
WO2009074733A2 (fr)	2009-06-18
HN2010000533A (es)	2013-07-08
PT2039682E (pt)	2010-09-27
ZA200808062B (en)	2009-11-25
JP4903187B2 (ja)	2012-03-28
NI201000038A (es)	2010-07-15
AU2008217013B2 (en)	2012-08-16
TN2010000111A1 (fr)	2011-09-26
PE20091190A1 (es)	2009-08-09
MA30320B1 (fr)	2009-04-01
FR2921365A1 (fr)	2009-03-27
PL2039682T3 (pl)	2010-10-29
KR101070056B1 (ko)	2011-10-04
ECSP10010040A (es)	2010-04-30
CR11320A (es)	2010-06-29
EP2236495A1 (fr)	2010-10-06
DE602008002027D1 (de)	2010-09-16
ES2349493T3 (es)	2011-01-04
AP2010005204A0 (en)	2010-04-30
US20090082393A1 (en)	2009-03-26
TWI370118B (en)	2012-08-11
AU2008217013B8 (en)	2012-10-04
DK2039682T3 (da)	2010-11-08
KR20090031298A (ko)	2009-03-25
RS51433B (sr)	2011-04-30
PA8796701A1 (es)	2009-09-17
EA015092B1 (ru)	2011-06-30
CN101391973A (zh)	2009-03-25
AU2008217013A1 (en)	2009-04-09
CY1110782T1 (el)	2015-06-10
GEP20125479B (en)	2012-04-25

Publication	Publication Date	Title
AU2017251683C1 (en)	2019-11-14	Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
ES2316613T3 (es)	2009-04-16	Derivados de acido crboxilico y composiciones farmaceuticas que contienen los mismos como ingrediente activo.
KR101186386B1 (ko)	2012-09-26	Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도
JP4177484B2 (ja)	2008-11-05	置換されたジアミノカルボン酸
ES2711363T3 (es)	2019-05-03	Derivados de (2-ureidoacetamido)alquilo como moduladores del receptor 2 de péptidos formilados
JP2005504121A5 (pl)	2005-12-22
US20030134801A1 (en)	2003-07-17	Thrombin inhibitors
RU2004125178A (ru)	2005-06-10	Фармацевтические композиции, включающие валсартан и ингибиторы нейтральной эндопептидазы (nep)
RU2004129584A (ru)	2005-05-27	Производное 8-азапростагландина и агент, содержащий данное соединение в качестве активного ингредиента
JPH0730022B2 (ja)	1995-04-05	グアニジン
RU2000118792A (ru)	2002-08-10	ПРОИЗВОДНЫЕ БЕНЗАМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА СВЕРТЫВАНИЯ КРОВИ Хa
ES2675216T3 (es)	2018-07-09	Derivados de ácido bisfenil-butanoico fosfónico sustituido como inhibidores de NEP (endopeptidasa neutra)
JPH04226913A (ja)	1992-08-17	オキザリルアミノ酸誘導体およびそれを含有する医薬
KR20010082515A (ko)	2001-08-30	아미디노 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
JP2008530101A5 (pl)	2009-04-09
AU751701B2 (en)	2002-08-22	Ace inhibitor-MMP inhibitor combinations
JP2013517295A5 (pl)	2013-12-12
RU2008122712A (ru)	2009-12-20	Комбинация органических соединений
CN109803657A (zh)	2019-05-24	药物组合物
CA2639700A1 (fr)	2009-03-21	Nouveaux sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine a des acides donneurs de no, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20010083134A (ko)	2001-08-31	아테롬성 동맥경화증 병소의 치료를 위한 ａｃａｔ 및ｍｍｐ 억제제의 병용 투여
KR940006770B1 (ko)	1994-07-27	머캅토-아실아미노산 고혈압 치료제
JP2009507878A (ja)	2009-02-26	２−（アミノメチル）−５−クロロベンジルアミド誘導体および凝固因子Ｘａの阻害剤としてのそれらの使用
RU2000113850A (ru)	2002-05-10	Замещенные анилиды
EA000743B1 (ru)	2000-02-28	Производные фосфоновой кислоты, обладающие ингибирующей активностью в отношении металлопептидаз